Fulvestrant Lek 250 mg raztopina za injiciranje v napolnjeni injekcijski brizgi Slovenia - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fulvestrant lek 250 mg raztopina za injiciranje v napolnjeni injekcijski brizgi

lek d.d. - fulvestrant - raztopina za injiciranje v napolnjeni injekcijski brizgi - fulvestrant 250 mg / 1 brizga - fulvestrant

Fulvestrant Lek 250 mg raztopina za injiciranje v napolnjeni injekcijski brizgi Slovenia - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fulvestrant lek 250 mg raztopina za injiciranje v napolnjeni injekcijski brizgi

lek d.d. - fulvestrant - raztopina za injiciranje v napolnjeni injekcijski brizgi - fulvestrant 250 mg / 1 brizga - fulvestrant

Fulvestrant EVER Pharma 250 mg raztopina za injiciranje v napolnjeni injekcijski brizgi Slovenia - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fulvestrant ever pharma 250 mg raztopina za injiciranje v napolnjeni injekcijski brizgi

fulvestrant - raztopina za injiciranje v napolnjeni injekcijski brizgi - fulvestrant 250 mg / 1 brizga - fulvestrant

Nexplanon 68 mg implantat Slovenia - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

nexplanon 68 mg implantat

n. v. organon, oss - etonogestrel - implantat - etonogestrel 68 mg / 1 implantat - etonogestrel

Abiraterone Mylan Uni Eropa - Sloven - EMA (European Medicines Agency)

abiraterone mylan

mylan ireland limited - abirateron acetat - prostatične neoplazme - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.